BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25282593)

  • 1. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed.
    Fedele S; Bedogni G; Scoletta M; Favia G; Colella G; Agrillo A; Bettini G; Di Fede O; Oteri G; Fusco V; Gabriele M; Ottolenghi L; Valsecchi S; Porter S; Fung PP; Saia G; Campisi G; Bedogni A
    Br J Oral Maxillofac Surg; 2015 Jan; 53(1):13-7. PubMed ID: 25282593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
    J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study.
    Kwon JW; Park EJ; Jung SY; Sohn HS; Ryu H; Suh HS
    J Dent Res; 2015 Sep; 94(9 Suppl):212S-9S. PubMed ID: 26001708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review.
    Nicolatou-Galitis O; Razis E; Galiti D; Galitis E; Labropoulos S; Tsimpidakis A; Sgouros J; Karampeazis A; Migliorati C
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Dec; 120(6):699-706. PubMed ID: 26455289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan.
    Yuh DY; Chang TH; Huang RY; Chien WC; Lin FG; Fu E
    J Dent; 2014 Oct; 42(10):1343-52. PubMed ID: 24907558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Kunchur R; Need A; Hughes T; Goss A
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
    Mavrokokki T; Cheng A; Stein B; Goss A
    J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
    Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.
    Carmagnola D; Celestino S; Abati S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):e10-5. PubMed ID: 18801674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system.
    Schiodt M; Reibel J; Oturai P; Kofod T
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Feb; 117(2):204-13. PubMed ID: 24332520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature.
    Gavaldá C; Bagán JV
    Med Oral Patol Oral Cir Bucal; 2016 May; 21(3):e260-70. PubMed ID: 26827066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians.
    El Osta L; El Osta B; Lakiss S; Hennequin M; El Osta N
    Support Care Cancer; 2015 Sep; 23(9):2825-31. PubMed ID: 25672288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
    You Tm; Lee KH; Lee SH; Park W
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone.
    Abtahi J; Agholme F; Sandberg O; Aspenberg P
    J Oral Pathol Med; 2012 Jul; 41(6):494-9. PubMed ID: 22268631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.
    Nicolatou-Galitis O; Kouri M; Papadopoulou E; Vardas E; Galiti D; Epstein JB; Elad S; Campisi G; Tsoukalas N; Bektas-Kayhan K; Tan W; Body JJ; Migliorati C; Lalla RV;
    Support Care Cancer; 2019 Feb; 27(2):383-394. PubMed ID: 30353228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: report of 2 cases.
    Lee JJ; Cheng SJ; Wang YP; Jeng JH; Chiang CP; Kok SH
    Head Neck; 2013 Jan; 35(1):E6-10. PubMed ID: 21523843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.